Physician profile
Jenny Dickson
NPI 1023488939
$38,991.29
in general payments reported to CMS, 2019-2025
32 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,344 · 2022: $5,215 · 2023: $5,405 · 2024: $8,412 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $1,960 · Education: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,344.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,650.00 |
| Consulting Fee | $1,960.00 |
| Education | $478.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $12,173.99 | 2021-2025 | Nemluvio, Twyneo, Aklief |
| Abbvie INC. | $3,962.30 | 2021-2025 | |
| Leo Pharma INC. | $2,539.30 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Genzyme Corporation | $2,282.11 | 2021-2025 | |
| Ucb, INC. | $2,161.68 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $2,011.69 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $1,639.88 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $1,533.09 | 2021-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $1,464.94 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $1,313.01 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,190.26 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $1,174.66 | 2023-2024 | Vtama |
| Lilly USA, LLC | $879.03 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $875.07 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $505.14 | 2021-2025 | Ilumya, Winlevi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $487.48 | 2021-2025 | Otezla, Otezla |
| Organon LLC | $467.05 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $395.21 | 2021-2025 | Jublia |
| Vyne Pharmaceuticals INC. | $340.22 | 2021 | |
| Epi Health, LLC | $281.82 | 2021-2022 | |
| Almirall LLC | $222.23 | 2021-2023 | Seysara |
| Mayne Pharma Commercial LLC | $213.53 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.14 | 2022-2024 | Spevigo |
| Journey Medical Corporation | $182.09 | 2021-2025 | |
| Verrica Pharmaceuticals INC. | $124.15 | 2024 | Ycanth |
| Regeneron Pharmaceuticals, INC. | $99.70 | 2023 | Dupixent |
| Botanix Sb INC | $84.70 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $57.96 | 2021 | |
| Paratek Pharmaceuticals, INC. | $55.25 | 2022-2025 | Nuzyra |
| Dermira, INC. | $43.83 | 2021 | |
| Biofrontera INC. | $13.44 | 2022 | |
| Merz North America, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.